Comparison of [123I]MIBG and [131I]MIBG for imaging of neuroblastoma and other neural crest tumors

Quarterly Journal of Nuclear Medicine and Molecular Imaging

Volumn 57, Issue 1, 2013, Pages 21-28

  Liu, B ^a,b   Zhuang, H ^b   Servaes, S ^b  

^a SICHUAN UNIVERSITY   (China)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Dose fractionation; Neural crest; Neuroblastoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; (3 IODOBENZYL)GUANIDINE; DIAGNOSTIC AGENT; RADIOACTIVE IODINE;

BRAIN SCINTISCANNING; DOSIMETRY; DRUG ABSORPTION; HUMAN; MOLECULAR IMAGING; NEURAL CREST; NEUROBLASTOMA; NEUROIMAGING; PARAGANGLIOMA; PHEOCHROMOCYTOMA; PROGRESSION FREE SURVIVAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; REVIEW; SCINTILLATION CAMERA; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ADULT; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; COMPARATIVE STUDY; FEMALE; MALE; METHODOLOGY; RADIOMETRY; SCINTISCANNING; TIME; TISSUE DISTRIBUTION; WHOLE BODY IMAGING;

3-IODOBENZYLGUANIDINE; ADULT; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; DOSE FRACTIONATION; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEUROBLASTOMA; PHEOCHROMOCYTOMA; RADIOMETRY; TIME FACTORS; TISSUE DISTRIBUTION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; WHOLE BODY IMAGING;

MLCS; MLOWN;

EID: 84876533813     PISSN: 18244785     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Wieland DM, Wu J, Brown LE, Mangner TJ, Swanson DP, Beierwaltes WH. Radiolabeled adrenergi neuron-blocking agents: adrenomedullary imaging with [131I]iodobenzylguanidine. J Nucl Med 1980;21:349-53. (Pubitemid 10100562)
2. Boubaker A, Bischof Delaloye A. MIBG scintigraphy for the diagnosis and follow-up of children with neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:388-402.
3. Taggart D, Dubois S, Matthay KK. Radiolabeled metaiodobenzylguanidine for imaging and therapy of neuroblastoma. Q J Nucl Med Mol Imaging 2008;52:403-18.
4. Wiseman GA, Pacak K, O'Dorisio MS, Neumann DR, Waxman AD, Mankoff DA et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial. J Nucl Med 2009;50:1448-54.
5. Rufini V, Calcagni ML, Baum RP. Imaging of neuroendocrine tumors. Semin Nucl Med 2006;36:228-47. (Pubitemid 43817847)
6. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008;52:419-29.
7. Khan MU, Morse M, Coleman RE. Radioiodinated metaiodobenzylguanidine in the diagnosis and therapy of carcinoid tumors. Q J Nucl Med Mol Imaging 2008;52:441-54.
8. Castellani MR, Seregni E, Maccauro M, Chiesa C, Aliberti G, Orunesu E et al. MIBG for diagnosis and therapy of medullary thyroid carcinoma: is there still a role? Q J Nucl Med Mol Imaging 2008;52:430-40.
9. Shimada H, Ambras IM, Dehner LP, Hata J, Joshi W, Roald B et al. The International Neuroblastoma Pathology Classification (the Shimada system). Cancer 1999;86:364-72. (Pubitemid 29327594)
10. Shimada H, Ambros IM, Dehner LP, Hata J, Joshi VV, Roald B. Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349-63. (Pubitemid 29327593)
11. Peuchmaur M, d'Amore ES, Joshi W, Hata J, Roald B, Dehner LP et al. Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular. Cancer 2003;98:2274-81. (Pubitemid 37392433)
12. Lonergan GJ, Schwab CM, Suarez ES, Carlson CL. Neuroblastoma, ganglioneuroblastoma, and ganglioneuroma: radiologic-pathologie correlation. Radiographics 2002;22:911-34.
13. Maris JM, Hogarty MD, Bagateli R, Cohn SL. Neuroblastoma. Lancet 2007;369:2106-20. (Pubitemid 46935947)
14. Johnson K, McGlynn B, Saggio J, Baniewicz D, Zhuang H, Maris JM et al. Safety and efficacy of tandem 1311-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma. Pediatr Blood Cancer 2011;57:1124-9.
15. Sharp SE, Gelfand MJ, Shulkin BL. Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med 2011;41:345-53.
16. Kushner BH. Neuroblastoma: a disease requiring a multitude of imaging studies. J Nucl Med 2004;45:1172-88. (Pubitemid 47611663)
17. Pfluger T, Schmid I, Coppenrath E, Weiss M. Modern nuclear medicine evaluation of neuroblastoma. Q J Nucl Med Mol Imaging 2010;54:389-400.
18. Sisson JC, Yanik GA. Theranostics: evolution of the radiopharmaceutical meta-iodobenzylguanidine in endocrine tumors. Semin Nucl Med 2012;42:171-84.
19. Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010;362:2202-11.
20. Kimmig B, Brandeis WE, Eisenhut M, Bubeck B, Hermann HJ, zum Winkel K. Scintigraphy of a neuroblastoma with 1-131 meta-iodobenzylguanidine. J Nucl Med 1984;25:773-5.
21. Timmers HJ, Chen CC, Carrasquillo JA, Whatley M, Ling A, Havekes B et al. Comparison of 18F-fluoro-L-DOPA, 18F-fluorodeoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J Clin Endo Metab 2009;94:4757-67.
22. Lu MY, Liu YL, Chang HH, Jou ST, Yang YL, Lin KH et al. Characterization of neuroblastic tumors using 18F-FDOPA PET. J Nucl Med 2012.
23. Chen L, Li F, Zhuang H, Jing H, Du Y, Zeng Z. 99mTc-HYN-IC-TOC scintigraphy is superior to 131I-MIBG imaging in the evaluation of extraadrenal pheochromocytoma. J Nucl Med 2009;50:397-400.
24. Melzer HI, Coppenrath E, Schmid I, Albert MH, von Schweinitz D, Tudball C et al. 123I-MIBG scintigraphy/SPECT versus (1)(8) F-FDG PET in paediatric neuroblastoma. Euro J Nucl Med Mol Imaging 2011;38:1648-58.
25. Bombardieri E, Coliva A, Maccauro M, Seregni E, Orunesu E, Chiti A et al. Imaging of neuroendocrine tumours with gamma-emitting radiopharmaceuticals. Q J Nud Med Mol Imaging 2010;54:3-15.
26. Chen L, Li F, Zhuang H, Jing H, Du Y, Zeng Z. Cardiac pheochromocytomas detected by Tc-99m-hydrazinonicotinyl-Tyr3-octreotide (HYNIC-TOC) scintigraphy. Clin Nucl Med 2007;32:182-5.
27. Grassi I, Nanni C, Vicennati V, Castellucci P, Allegri V, Montini GC et al. I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report. Clin Nucl Med 2011;36:124-6.
28. Vavere AL, Butch ER, Dearling JL, Packard AB, Navid F, Shulkin BL et al. 64Cu-p-NH2-Bn-DOTA-hul4.18K322A, a PET Radiotracer Targeting Neuroblastoma and Melanoma. J Nucl Med 2012;53:1772-8.
29. Rufini V, Shulkin B. The evolution in the use of MIBG in more than 25 years of experimental and clinical applications. Q J Nucl Med Mol Imaging 2008;52:341-50.
30. Jacobson AF, Deng H, Lombard J, Lessig HJ, Black RR. 1231-meta- iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis. J Clin Endo Metab 2010;95:2596-606.
31. Silberstein EB. Radioiodine: the classic theranostic agent. Semin Nucl Med 2012;42:164-70.
32. Bombardieri E, Giammarile F, Aktolun C, Baum RP, Bischof Delaloye A, Maffioli L et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: procedure guidelines for tumour imaging. Euro J Nucl Med Mol Imaging 2010;37:2436-46.
33. Radiation dose to patients from radiopharmaceuticals. A report of a Task Group of Committee 2 of the International Commission on Radiological Protection. Ann ICRP 1987;18:1-377.
34. Radiation dose to patients from radiopharmaceuticals (addendum 2 to ICRP publication 53). Ann ICRP 1998;28:1-126.
35. Shulkin BL, Shapiro B. Current concepts on the diagnostic use of MIBG in children. J Nucl Med 1998;39:679-88. (Pubitemid 28175849)
36. Lassmann M, Biassoni L, Monsieurs M, Franzius C, Jacobs F; EANM Dosimetry and Paediatrics Committees. The new EANM paediatric dosage card. Euro J Nucl Med Mol Imag 2007;34:796-8.
37. Gelfand MJ, Parisi MT, Treves ST, Pediatric Nuclear Medicine Dose Reduction W. Pediatric radiopharmaceutical administered doses: 2010 North American consensus guidelines. J Nud Med 2011;52:318-22.
38. Tsuchimochi S, Nakajo M, Nakabeppu Y, Tani A. Metastatic pulmonary pheochromocytomas: positive I-123 MIBG SPECT with negative I-131 MIBG and equivocal I-123 MIBG planar imaging. Clin Nucl Med 1997;22:687-90. (Pubitemid 28049449)
39. Shulkin BL, Shapiro B, Francis IR, Dorr R, Shen SW, Sisson JC. Primary extra-adrenal pheochromocytoma: positive I-123 MIBG imaging with negative I-131 MIBG imaging. Clin Nucl Med 1986;11:851-4. (Pubitemid 17221351)
40. Nakatani T, Hayama T, Uchida J, Nakamura K, Takemoto Y, Sugimura K. Diagnostic localization of extra-adrenal pheochromocytoma: comparison of (123)I-MIBG imaging and (131)I-MIBG imaging. Oncol Rep 2002;9:1225-7.
41. Furuta N, Kiyota H, Yoshigoe F, Hasegawa N, Ohishi Y. Diagnosis of pheochromocytoma using [123I]-compared with [131I]-metaiodobenzylguanidine scintigraphy. Int J Urol 1999;6:119-24. (Pubitemid 30406825)
42. Ishii S, Shishido F, Miyajima M, Sakuma K, Kikuchi K. Pheochromocytoma in multiple endocrine neoplasia type 2A: positive 123I MIBG with negative CT and equivocal 131I MIBG imaging. Clin Nucl Med 2012;37:596-8.
43. Gelfand M. 123I MIBG and 131I MIBG imaging in children with neuroblastoma [Abstract]. J Nucl Med 1996;37:35P.
44. Sinon BH CA, de Kraker J, van Steeg G, Valdes Olmos RA. Iodine-123-MIBG or 13H-MIBG for imaging of neuroblastoma? a comparative study [Abstract]. Eur J Nucl Med 1992;19:589.
45. Kushner BH, Yeh SD, Kramer K, Larson SM, Cheung NK. Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. J Clin Oncol 2003;21:1082-6. (Pubitemid 46594137)
46. Naranjo A, Parisi MT, Shulkin BL, London WB, Matthay KK, Kreissman SG et al. Comparison of 123 I-metaiodobenzylguanidine (MIBG) and 131I-MIBG semi-quantitative scores in predicting survival in patients with stage 4 neuroblastoma: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;56:1041-5.
47. Fukuoka M, Taki J, Mochizuki T, Kinuya S. Comparison of diagnostic value of I-123 MIBG and high-dose I-131 MIBG scintigraphy including incremental value of SPECT/CT over planar image in patients with malignant pheochromocytoma/ paraganglioma and neuroblastoma. Clin Nucl Med 2011;36:1-7.
48. Rufini V, Fisher GA, Shulkin BL, Sisson JC, Shapiro B. Iodine-123-MIBG imaging of neuroblastoma: utility of SPECT and delayed imaging. J Nucl Med 1996;37:1464-8. (Pubitemid 26321623)
49. Gelfand MJ, Elgazzar AH, Kriss VM, Masters PR, Golsch GJ. Iodine-123-MIBG SPECT versus planar imaging in children with neural crest tumors. J Nucl Med 1994;35:1753-7. (Pubitemid 24346793)
50. Fitzgerald PA, Goldsby RE, Huberty JP, Price DC, Hawkins RA, Veatch JJ et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci 2006;1073:465-90.
51. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-8.
52. Klingebiel T, Reuland P, Feine U, Niethammer D. [Follow-up evaluation of metastatic neuroblastoma using high dose [131I-meta]iodobenzylguanidine). Nuklearmedizin 1992;31:209-12.
53. Parisi MT, Matthay KK, Huberty JP, Hattner RS. Neuroblastoma: dose-related sensitivity of MIBG scanning in detection. Radiology 1992;184:463-7.
54. Yang J, Codreanu I, Servaes S, Zhuang H. I-131 MIBG post-therapy scan is more sensitive than I-123 MIBG pretherapy scan in the evaluation of metastatic neuroblastoma. Nucl Med Commun 2012;33:1134-7.
55. Campbell L, Mouratidis B, Sullivan P. Improved detection of disseminated pheochromocytoma using post therapy I-131 MIBG scanning. Clin Nucl Med 1996;21:960-3. (Pubitemid 26412221)
56. Kayano D, Taki J, Fukuoka M, Wakabayashi H, Inaki A, Nakamura A et al. Low-dose (123)I-metaiodobenzylguanidine diagnostic scan is inferior to (131)I-metaiodobenzylguanidine posttreatment scan in detection of malignant pheochromocytoma and paraganglioma. Nucl Med Commun 2011;32:941-6.
57. Giammarile F, Lumbroso J, Ricard M, Aubert B, Hartmann O, Schlumberger M et al. Radioiodinated metaiodobenzylguanidine in neuroblastoma: influence of high dose on tumour site detection. Eur J Nucl Med 1995;22:1180-3.
58. Hickeson MP, Charron M, Maris JM, Brophy P, Kang TI, Zhuang H et al. Biodistribution of post-therapeutic versus diagnostic (13I)I-MIBG scans in children with neuroblastoma. Pediatr Blood Cancer 2004;42:268-74. (Pubitemid 38235078)